A phase II trial of zd0473 in patients with metastatic breast cancer. A National Cancer Institute of Canada clinical trials group study (NCIC CTG-IND 129)
T.A. Vandenberg , K.A. Gelmon , L. Panasci , M. Crump
European Journal of Cancer 37
4
2001
A phase I study of T900607 given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 130)
K.A. Gelmon , K. Belanger , C. Britton , D. Soulières
European Journal of Cancer 37
2001
A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 131)
K.A. Gelmon , D. Stewart , D. Ayers , D. Fry
European Journal of Cancer 37
2
2001
19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)
P. Bedard , M. Mates , K.A. Gelmon , J. Hilton
Annals of Oncology 31
2020
Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio
LK Seymour , G Le Teuff , M Tsao , E Brambilla
Annals of Oncology 25 iv58
2
2014
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200
Q. S.-C. Chu , T.O. Nielsen , T. Alcindor , A. Gupta
Annals of Oncology 26 ( 5) 973 -981
26
2015
A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.
K.A. Gelmon , T.A. Vandenberg , L. Panasci , B. Norris
Annals of Oncology 14 ( 4) 543 -548
14
2003
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131
K.A. Gelmon , D. Stewart , K.N. Chi , S. Chia
Annals of Oncology 15 ( 7) 1115 -1122
18
2004
CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)
S.J. Hotte , E. Winquist , K.N. Chi , S.L. Ellard
Annals of Oncology 30
1
2019
Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)
J.C. Wells , A. Sidhu , K. Ding , D.Y.C. Heng
Annals of Oncology 30 v720
1
2019
Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
D. Hao , P.M. Ellis , S.A. Laurie , R.A. Juergens
Annals of Oncology 30
2019
Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
LK Seymour , RD Dansey , WR Bezwoda
British Journal of Cancer 70 ( 3) 526 -530
7
1994
Prognostic factors in chronic m. yeloid leukaem. ia-im. portance ofstaging or disease biology
S Ariad , LK Seymour , AP Macphail , EA Weaving
SAMJ 81 299 -299
4
1992
A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group study (NCIC CTG-IND 131).
D Stewart , KA Gelmon , D Ayers , D Fry
CLINICAL CANCER RESEARCH 7 ( 11) 3751S -3751S
1
2001
Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio
LK Seymour , G Le Teuff , M Tsao , E Brambilla
Annals of Oncology 25 iv58
2
2014
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
G. Goss , H. Hirte , W. H. Miller , I. A. J. Lorimer
Investigational New Drugs 23 ( 2) 147 -155
30
2005
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
G. Goss , L. L. Siu , I. Gauthier , E. X. Chen
Cancer Chemotherapy and Pharmacology 58 ( 5) 703 -710
8
2006
NCIC CLINICAL TRIALS GROUP (NCIC CTG) A RANDOMIZED PHASE II STUDY OF REOLYSIN IN COMBINATION WITH FOLFOX6/BEVACIZUMAB OR FOLFOX6/BEVACIZUMAB ALONE IN PATIENTS WITH
LESLEY SEYMOUR , SENIOR BIOSTATISTICIAN , DONGSHENG TU
Estimation of PR and ER by immunocytochemistry in breast cancer
LESLIE SEYMOUR , FC P SA KAREN MEYER , JAN ESSER , MBB CH
MODULATION OF THE BIOLOGIC BEHAVIOUR OF
33
1998
tre Aurélie, Leighl Natasha B, Shepherd Frances A. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials
K Hicks Lisa , C Cheung Matthew , Hasan Baktiar Ding Keyue , Le Ma Seymour Lesley
Cancer
2
2009